 |
97 Diseases |  |
239 Trials |
|
239 Trials |  |
14341 News |  |
| «12345678910111213...166167» |
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants. (Pubmed Central) - Mar 25, 2024
In NVAF patients treated with apixaban, edoxaban and rivaroxaban, some coagulation parameters exhibited age-related variation. However, the response of mdPT to drug concentration was consistent across age categories.
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Biomarker, Journal, IO biomarker: Perioperative Treatment with Rivaroxaban and Dabigatran on Changes of Coagulation and Platelet Activation Biomarkers following Left Atrial Appendage Closure. (Pubmed Central) - Mar 24, 2024
However, the response of mdPT to drug concentration was consistent across age categories. Furthermore, the plasma levels of platelet activation biomarkers (CD40L and sP-selectin) in both LA and LAA groups were significantly lower after anticoagulation with rivaroxaban, as compared to dabigatran treatment (CD40L: 554.62
- | rivaroxaban / Generic mfg.
Journal: Mid-term analysis of prospective cohort study of rivaroxaban in preventing CRT in breast cancer (Pubmed Central) - Mar 22, 2024
Rivaroxaban is proved effective and very safe in the treatment of CRT, and does not affect the concurrent chemotherapy. Medical personnel should carry out the policy of "early prevention, early detection and early treatment" for CRT so as to improve the patients' quality of life.
- | Savaysa (edoxaban) / Daiichi Sankyo
New P3 trial: RESTARTtlCrH: Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage (clinicaltrials.gov) - Mar 21, 2024
P3, N=1084, Not yet recruiting, Sponsor: Walton Centre NHS Foundation Trust
- | Avastin (bevacizumab) / Roche
Journal: Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications. (Pubmed Central) - Mar 21, 2024
Bevacizumab is a humanized monoclonal anti-VEGF antibody often given in combination with fluorouracil-based chemotherapy as therapy for metastatic colorectal cancer (mCRC)...21 patients were identified who received bevacizumab and either apixaban or rivaroxaban for mCRC treatment...No patient experienced adverse thrombotic events. Patients with mCRC treated with bevacizumab and apixaban with no history of aspirin use within three years have a relatively low risk of bleeding that warrants treatment discontinuation.
- || Savaysa (edoxaban) / Daiichi Sankyo
Retrospective data, Review, Journal: Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Mar 21, 2024
DOACs demonstrate comparable efficacy but exhibit different safety profiles. Apixaban may confer an antithrombotic benefit without an increased risk for bleeding, distinguishing it from other contemporary anticoagulation strategies in patients with active cancer and VTE.
- | warfarin / Generic mfg.
Journal: Direct oral anticoagulants compared with warfarin in patients with left ventricular thrombus: a cohort study from China. (Pubmed Central) - Mar 20, 2024
DOAC might be an alternative to warfarin for the treatment of LV thrombus. However, further large prospective studies are required to explore the efficacy and safety of DOAC in patients with LV thrombus.
- || rivaroxaban / Generic mfg.
Retrospective data, Review, Journal: Assessing the Safety and Efficacy of Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation: A Systemic Review and Meta-Analysis. (Pubmed Central) - Mar 18, 2024
Standard dosing of rivaroxaban emerges as a preferred strategy for stroke prevention, balancing efficacy and safety. Clinical decision-making should consider individual patient characteristics and future research should delve into specific subpopulations and long-term outcomes to further refine treatment guidelines.
- Impact of increasing concentration of direct oral anticoagulants and their impact on rotem variables; an experimental study () - Mar 18, 2024 - Abstract #ISICEM2024ISICEM_1009;
CT in the other ROTEM assays was also affected in a similar manner while the impact on increasing DOAC concentrations on CFT and ?-angle were not significant. In clinical practice, CT can be used as a surrogate marker for DOAC concentration.
- | Lumakras (sotorasib) / Amgen
New P4 trial: ROSIE: Rivaroxaban Sotorasib Interaction Study (clinicaltrials.gov) - Mar 17, 2024
P4, N=22, Recruiting, Sponsor: Radboud University Medical Center
- Jakafi (ruxolitinib) / Incyte, Soliris (eculizumab) / AstraZeneca
Medical management of portal vein thrombosis in patients without cirrhosis (Gold Room) - Mar 16, 2024 - Abstract #EASLILC2024EASL_ILC_23;
Preliminary data with ruxolitinib or pegylated-interferon in small series is promising. In patients with splanchnic vein thrombosis (including Budd-Chiari syndrome) associated with paroxysmal nocturnal haemoglobinuria (PNH), treatment with eculizumab significantly improved survival, and recurrent thrombosis in and outside the splanchnic veins.7 In one case series, in 18 patients treated with C5 inhibition alone without therapeutic anticoagulation (interrupted in 12), two had recurrent thrombosis suggesting that discontinuation of anticoagulation in PNH patients well-controlled on terminal complement inhibition may be safe.8 Other data in Beh
- || rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Observational data, Review, Journal: Drug-related problems associated with direct oral anticoagulants: an observational cross-sectional study of medical record review by pharmacists in a large teaching hospital. (Pubmed Central) - Mar 15, 2024
Inappropriate drug regimen was the most common DOAC-associated DRP. Impaired renal function and patients with AF increased the likelihood of DOAC-associated DRPs.
- Savaysa (edoxaban) / Daiichi Sankyo
RISK OF UPPER GASTROINTESTINAL BLEEDING IN DIRECT ORAL ANTICOAGULANT USERS: AN ASIAN POPULATION-BASED PROPENSITY-SCORE ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7139;
Findings were consistent with other studies in Western population. Caution should be exercised on DOAC prescription, particularly in patients at higher risk of UGIB.
- PREDICTING MAJOR BLEEDING IN PATIENTS RECEIVING ANTICOAGULANT THERAPY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7131;
Our results clearly demonstrate that certain variables are associated with major bleeding in patients on OACs, but none of these are decisively predictive. Further studies should focus on identifying reliable risk factors for MB before attempting to develop further risk scores.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
POST-ENDOSCOPIC DOAC MANAGEMENT AND OUTCOMES IN ACUTE UPPER GASTROINTESTINAL BLEEDING: PRACTICE TRENDS AT A TERTIARY REFERRAL CENTER (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7130;
Lethal thrombotic complications occurred only among patients with DOAC discontinuation. Multidisciplinary discussion on DOAC management post-AUGIB are necessary to individually risk-stratify patients.
- Savaysa (edoxaban) / Daiichi Sankyo
OPTIMAL DIRECT ORAL ANTICOAGULANT IN UPPER GASTROINTESTINAL ENDOSCOPIC SUBMUCOSAL DISSECTION (150AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_6587;
[Conclusions] In this large-scale database study, we first found the risk of ischemic stroke and delayed bleeding in upper GI ESD in patients with each DOAC. Based on the priority of risk of ischemic stroke compared with the risk of delayed bleeding and lower risk of both ischemic stroke and delayed bleeding, rivaroxaban might be optimal among the four DOACs in upper GI ESD.
- Savaysa (edoxaban) / Daiichi Sankyo
ASSOCIATION OF DIRECT ORAL ANTICOAGULANT AND DELAYED BLEEDING WITH PHARMACOKINETICS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4979;
The incidence of post-ESD bleeding was significantly higher in patients with higher age (P = 0.028), concomitant antiplatelet drugs (P <0.001), aspirin (P = 0.003), and thienopyridine (P <0.001) compared with respective non-bleeding patients. Although plasma DOAC concentration and plasma level/dose ratio at trough and T max varied widely among individuals, a significant correlation with plasma concentration and FXa activity was observed (apixaban: correlation coefficient, -0.893, p <0.001).
- warfarin / Generic mfg.
COMPARISION OF THE SEVERITY OF GASTROINTESTINAL BLEEDING AMONGST PATIENTS TREATED WITH WARFARIN AND DIRECT ORAL ANTICOAGULANTS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4870;
The final population included all patients that had a GIB while receiving apixaban, dabigatran, rivaroxaban, and warfarin during the study period. The severity of gastrointestinal bleeding in patients treated with warfarin and DOACs proved to be comparable.
- Savaysa (edoxaban) / Daiichi Sankyo
RISK OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY-RELATED BLEEDING WITH UNINTERRUPTED ANTICOAGULATION: A MULTI-CENTER RETROSPECTIVE COHORT STUDY (143ABC - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2704;
However, the absolute increase in bleeding risk was small (Risk difference 0.5%). Furthermore, rates of severe bleeding, as indicated by ICU admission and blood transfusion, was not statistically different beween the two cohorts.
- warfarin / Generic mfg.
EVALUATION OF RISK OF BLEEDING IN COMPARISON OF DOACS VERSUS WARFARIN IN CONCOMITANT LIVER CIRRHOSIS AND ATRIAL FIBRILLATION - A SYSTEMATIC REVIEW AND META-ANALYSIS (202B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2203;
Conclusions In summary, our study demonstrated the safe bleeding profile of DOACs in comparison with warfarin. However, these findings need to be validated with well-designed clinical studies.
- | Savaysa (edoxaban) / Daiichi Sankyo
Enrollment closed, Trial primary completion date: Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants (clinicaltrials.gov) - Mar 12, 2024
P=N/A, N=150, Active, not recruiting, Sponsor: Cardioangiologisches Centrum Bethanien
However, these findings need to be validated with well-designed clinical studies. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024
- rivaroxaban / Generic mfg., aspirin / Generic mfg., apixaban / Generic mfg.
Extended Pharmacological Thromboprophylaxis Post Robotic Prostatectomy with Pelvic Lymph Node Dissection (303B) - Mar 12, 2024 - Abstract #AUA2024AUA_2716;
The rate of VTE observed was 3. 125%, marginally higher than previously reported risks of VTE occurrence for patients undergoing RALP with PLND (0.
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up. (Pubmed Central) - Mar 12, 2024
Patients included in the study for multiple episodes of VTE presented a significantly higher risk of a new VTE recurrence during low-intensity DOAC. Our data suggest that low-dose DOACs may be effective and safe in secondary VTE prophylaxis in patients at high risk of VTE recurrence; however, attention might be needed in their choice in such a scenario for patients who experienced multiple episodes of VTE.
- Savaysa (edoxaban) / Daiichi Sankyo
Synthesis and biological studies of triazole-based small molecules as factor XIIa inhibitors | Poster Board #2211 (In-person; Poster Board #2211; Hall C (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_4850;
Our lab has employed a rationale design approach to identify lead inhibitors of FXIIa where an N-substituted triazole compound has been developed as a lead compound. Our project involves design, synthesis, and biological studies of N-amino triazole ester-based analogs.
- || rivaroxaban / Generic mfg.
Clinical, Journal: Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries. (Pubmed Central) - Mar 11, 2024
Our project involves design, synthesis, and biological studies of N-amino triazole ester-based analogs. This study provides further data from routine clinical practice that broadly support safety profile of rivaroxaban for VTE indication and complement findings from previous randomized clinical trials.
- || rivaroxaban / Generic mfg.
Review: Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy. (Pubmed Central) - Mar 9, 2024
Currently available data are insufficient to confirm the relationship between clinical or pharmacokinetic outcomes of rivaroxaban and gene polymorphisms. Proactive strategies are advised as a priority in clinical practice rather than detection of SNP genotyping.
- || Savaysa (edoxaban) / Daiichi Sankyo
Retrospective data, Review, Journal: Atrial Thrombosis Prevalence before Cardioversion or Catheter Ablation of Atrial Fibrillation: An Update Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists. (Pubmed Central) - Mar 9, 2024
In conclusion, in this large meta-analysis on AF patients, the prevalence of LAT by TEE evaluation performed before CV or CA appears lower in those treated with DOACs than VKAs. Additional research may help in better understanding differences among these classes of anticoagulant drugs in the setting of protection against AF-related left atrial thrombotic formation.
- | rivaroxaban / Generic mfg.
Journal: Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation. (Pubmed Central) - Mar 8, 2024
There were no statistically significant differences between the two groups in terms of DRT (1.4% vs. 2.7%, p = 0.60), minor bleeding (8.2% vs. 11.0%, p = 0.39), thromboembolic events (1.0% vs. 0.8%, p = 1.00), major bleeding (0.5% vs. 0.8%, p = 1.00), or death. A short course of twice-daily rivaroxaban following LAAC is a feasible alternative regimen with a low rate of major bleeding events, DRT, and thromboembolic events for patients with AF.
- || AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Clinical, Journal, Real-world evidence, Real-world: Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data. (Pubmed Central) - Mar 8, 2024
Finally, management of patients at high risk of thrombosis or recent arterial/venous thrombotic events needs to be further explored. In this current opinion, we address these urgent questions in the light of recent literature and clinical trial data.
- Oxemia (desidustat) / Zydus Lifesci
A CASE OF BLEEDING MULTIPLE TELANGIECTASIAS OF INTESTINE IN A DIALYSIS PATIENT ON LONG TERM HYPOXIA INDUCIBLE FACTOR - PROLYL HYDROXYLASE INHIBITOR(HIFPHI) TREATMENT (MON-337; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1769;
Thalidomide is useful for refractory GIB in patients who can tolerate the drug. The possible etiological role of HIF-PHI for intestinal telangiectasias needs to be considered.
- rivaroxaban / Generic mfg.
Acute renal infarction in a 52-year-old man using testosterone for muscle mass increase (SAT-271; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1675;
Renal infarction is a rare condition and in most cases the diagnosis is delayed. It is important to remember that clinical suspicion and rapid diagnosis can be essential for maintaining good renal function.
- EFFICACY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH NEPHROTIC SYNDROME: A MULTI-INSTITUTIONAL ANALYSIS (MON-309; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1661;
Anticoagulated patients with severely low albumin had fewer events than those with higher albumin, although this was not statistically significant. Because DOACS and warfarin are highly albumin-bound, it is possible that more unbound and active medication is the reason for this.
- rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
NEW ORAL ANTICOAGULANTS VERSUS VITAMIN K ANTAGONISTS IN PATIENTS WITH ATRIAL FIBRILLATION AND STAGE 5 CHRONIC KIDNEY DISEASE UNDER DIALYSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS (SUN-217; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1346;
Of these, 218 received NOACs (130 received apixaban; 88 received rivaroxaban), and 165 were treated with VKAs (116 received warfarin; 49 received phenprocoumon). This meta-analysis suggests that in patients with AF on dialysis, the use of NOACs was associated with a significant reduction in stroke and a numerically lower incidence of major bleeding than VKAs.
- Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Januvia (sitagliptin) / Merck (MSD)
Evaluating Healthcare Costs and Demographics of Medicare Part D Beneficiaries Impacted by First Top 10 Drugs Selected for Price Negotiations Under the Inflation Reduction Act (IRA) () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2177;
Lower negotiated prices would lower beneficiaries' drug costs and potentially increase access to the selected drug. Black, Hispanic, and Asian LIS beneficiaries will be disproportionately impacted by the price negotiations.
- rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
Adherence and Persistence of Oral Anticoagulants for Treatment of Atrial Fibrillation across Stroke and Bleeding Risk Strata () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1527;
Adherence and persistence rates vary across stroke risk by drug, but generally decrease with increased bleeding risk within stroke risk groups. Newer therapies with lower bleeding risk are needed.
- Economic Evaluation of Pharmacological Interventions to Prevent Venous Thromboembolism in Patients after Hip or Knee Arthroplasty: A Systematic Review () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1502;
From healthcare system perspective or payer perspective, rivaroxaban, fondaparinux sodium or dabigatran might gain more effectiveness or utility to prevent VTE in patients undergoing hip or knee arthroplasty. More HEE studies are needed for other pharmacological interventions and economic evaluating perspectives.
- Utilization of High-Dimensional Propensity Score and Targeted Maximum Likelihood Estimation with Machine Learning to Improve Causal Effect Estimation in Patients with Nonvalvular Atrial Fibrillation and Hypertension () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1466;
More HEE studies are needed for other pharmacological interventions and economic evaluating perspectives. Our study demonstrates that when using healthcare claims data, HDPS and TMLE with ML may reduce bias and produce robust causal estimates that align with a previous clinical trial with similar endpoints.
- rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
Treating Patients With Non-Valvular Atrial Fibrillation With Apixaban Provides Substantial Consumer Value and Surplus Compared With Warfarin and Rivaroxaban () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1430;
Apixaban is a valuable treatment option for patients with NVAF, providing significant consumer value and surplus compared with warfarin and rivaroxaban. Results indicate that the use of apixaban generates substantial value to patients with NVAF in the US.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Decision Model to Evaluate the Cost of Clinical Events Associated with Switching from Apixaban to Rivaroxaban Among Patients with Non-Valvular Atrial Fibrillation in Germany () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1424;
Results indicate that the use of apixaban generates substantial value to patients with NVAF in the US. Switching from apixaban to rivaroxaban among patients with NVAF was associated with a substantial increase in clinical event-related costs for the German public healthcare payer.
- Savaysa (edoxaban) / Daiichi Sankyo
Exploring Patient Preferences through Cross-Sectional Discrete Choice Experiment: An Insight into Once-Daily Stroke Prevention Treatments in Atrial Fibrillation in Asia () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1415;
Edoxaban was the favored once-daily DOAC over rivaroxaban among the patients in the PCP analyses. To guide shared decision-making, it's crucial to consider the distinct profiles of once-daily DOACs, ensuring the chosen option aligns with individual patient preferences.
- Savaysa (edoxaban) / Daiichi Sankyo
A Novel Approach to Estimating the Risk of Harm Due to Drug-Drug Interactions: An Exemplary Model With Common Mediations That Interact With Oral Anticoagulants () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1391;
The OAC GI bleeding risk calculator incorporates patient-level risk factors to estimate bleeding risk. The model allows clinicians to enhance share decision making when visiting patients on OAC that are receiving NSAIDs and/or antidepressants.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Decision Model to Evaluate the Cost of Clinical Events Associated with Switching from Apixaban to Rivaroxaban Among Patients with Non-Valvular Atrial Fibrillation in the United States () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1385;
The model allows clinicians to enhance share decision making when visiting patients on OAC that are receiving NSAIDs and/or antidepressants. Switching from apixaban to rivaroxaban among patients with NVAF was associated with a substantial increase in clinical event-related costs for US payers.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Utility of the ISPOR Presentations Database to Support the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation (DPN): An Apixaban and Rivaroxaban Case Study () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1373;
Switching from apixaban to rivaroxaban among patients with NVAF was associated with a substantial increase in clinical event-related costs for US payers. The ISPOR Presentations Database provides grey literature that can add HEOR evidence to CMS
- Cost-Effectiveness of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the Aristophanes Real-World Evidence Study () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1367;
The ISPOR Presentations Database provides grey literature that can add HEOR evidence to CMS Across all high-risk patient subgroups assessed in the ARISTOPHANES study, apixaban was dominant versus warfarin, dabigatran and rivaroxaban.
- abelacimab (MAA868) / Anthos Therap, Novartis, MorphoSys, Lonza
An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1346;
This is the first analysis assessing the cost-effectiveness of abelacimab, an investigational once-monthly, dual-acting FXI/FXIa inhibitor for people with AF at moderate-to-high risk of stroke. If approved, abelacimab could yield substantial cost savings.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
A Method to Estimate Effect of Treatment Switching By Assigning Pseudo-Switch Date Among Continuers () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1211;
If approved, abelacimab could yield substantial cost savings. The proposed method for assigning random switching time to continuers reduced bias in estimating the effect of treatment switching.
- Fatal Outcomes from Drug Interactions: Insights from the FDA Adverse Event Reporting System () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_378;
Despite the high frequency of reports involving specific drug families, it's important to recognize that not all fatal adverse reactions due to drug interactions may be identified. This study underscores the complexity of assessing drug interaction harms and the necessity for further research in this critical area.
- rivaroxaban / Generic mfg.
Cough-induced Bilateral Vertebral Artery Dissections in an Active Duty Service Member with Complete Angiographic Resolution (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3998;
Based on our literature review, bilateral VADs are uncommon and have never been described in the setting of severe coughing. This case highlights a unique cause of bilateral VADs and demonstrates that full healing is still achievable with medical therapy, despite the severity of the dissections.
- Rituxan (rituximab) / Roche
Recurrent Ischemic Strokes in a Patient With ITP: A Case Report and Literature Review (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3704;
Thrombocytopenia in ITP is not protective against thrombosis but certainly increases risk of bleeding in patients receiving anticoagulation, therefore management can be challenging. Additional research is required to guide stroke management particularly in those without conventional stroke risk factors.
- rivaroxaban / Generic mfg., apixaban / Generic mfg.
Intracerebral Hemorrhage Risk in Patients with Primary Brain Tumors Taking Direct Oral Anticoagulants as Compared with Low Molecular Weight Heparin (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3496;
This retrospective study suggests that DOACs are relatively safe in PBT patients, with a similar risk of ICH to LMWH. Prospective studies are needed to definitively establish the risk of anticoagulation in this population.